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Introduction: Oxaliplatin is a cytotoxic platinum compound that is in widespread use in the treatment of
gastrointestinal cancers. It has been occasionally associated with acute motor neuropathy, but the precise
mechanism is uncertain. To the best of our knowledge, we report the first case of a patient demonstrating post-
tetanic facilitation in the setting of transient bilateral abducens neuropathy and hypokalemia, after being infused
with oxaliplatin.
Case presentation: A 47-year-old Indian woman with metastatic gastric cancer was receiving an oxaliplatin
infusion at the initiation of her third cycle of palliative chemotherapy. She developed acute bilateral abducens
neuropathy with post-tetanic facilitation alongside acute laryngopharyngodysesthesia and hypokalemia. Following
supportive management, including potassium infusion and warming, her neurological signs and symptoms were
spontaneously resolved. This syndrome did not recur in subsequent cycles following prolongation of infusion
duration and the addition of supportive calcium and magnesium infusions.
Conclusion: The novel clinical observation of post-tetanic facilitation highlights a possible involvement of voltage-
gated channels at the presynaptic terminals in the mechanism of acute oxaliplatin neurotoxicity.
Introduction
Oxaliplatin is a recently developed cytotoxic platinum
compound that is in widespread use, particularly for the
treatment of gastrointestinal cancers [1]. The association
between oxaliplatin and acute and chronic sensory neuro-
pathy is well recognized, but acute motor neuropathy is
also reported, albeit much less frequently [2]. The exact
mechanisms of both acute and chronic neurotoxicity
remain uncertain, despite extensive clinical experience
with the compound. It is conventionally regarded that the
voltage-gated sodium channels are involved in mechan-
isms of acute neurotoxicity [3], possibly through a pathway
involving calcium ions [4]. The use of calcium and magne-
sium infusions is currently under investigation [5].
Case presentation
We report a novel observation in a 47-year-old Indian
woman with no comorbidities who developed acute
bilateral abducens neuropathy with post-tetanic facilita-
tion alongside acute hypokalemia after infusion of oxali-
platin. She was first diagnosed with peritoneal
carcinomatosis arising from metastatic gastric adenocar-
cinoma, and was commenced on a palliative chemother-
apy regimen of continuous infusion 5-fluorouracil (5-
FU) 200 mg/m
2/day and weekly oxaliplatin (50 mg abso-
lute dose). After the first cycle totaling 150 mg oxalipla-
tin, during which significant clinical and radiological
improvement in her intestinal function was documented
permitting administration of oral medication, her regi-
men was modified to a three-weekly regimen of oxali-
platin (130 mg/m
2 on day 1 over 2 hours) and
capecitabine (2000 mg/m
2/day on day 1 evening - day
15 morning) (XELOX). One hour into the infusion of
oxaliplatin of the 2nd cycle of XELOX, she developed
acute neuropathy comprising acute bilateral abducens
neuropathy, dysarthria, laryngopharyngodysesthesia,
perioral and peripheral numbness. In addition to oxali-
platin, she had received 8 mg of intravenous dexametha-
sone and 8 mg of intravenous ondansetron as
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ications other than capecitabine up to one week pre-
viously. The patient demonstrated physical signs
consistent with bilateral abducens neuropathy, with
bilateral gaze-evoked diplopia. Surprisingly, post-tetanic
facilitation was observed, with unilateral resolution of
diplopia and abducens neuropathy following sustained
lateral gaze over one minute. Contralateral abducens
neuropathy remained unchanged following apparent
resolution of the unilateral abducens neuropathy. The
apparently resolved unilateral abducens neuropathy
recurred following a two-minute rest. Decreased tendon
reflexes diffusely were noted, but no focal or generalized
weakness was found. New electrocardiographic changes
in terms of diffuse T-wave inversions were noted, as
well as mild elevation of her serum creatine kinase-MB
(CK-MB) levels by mass assay. Also noted was a serial
decrease over 16 hours (7.0 μg/L immediately, 5.2 μg/L
8h o u r sl a t e ra n d3 . 9μg/L 16 hours later), but the dif-
fuse T-wave inversions persisted. Corresponding serial
serum creatine kinase (CK) levels were 72 μg/L, 63 μg/L
and 52 μg/L, and troponin-T levels were not elevated at
any of these three-time points.
Baseline blood counts and electrolytes drawn two days
prior were unremarkable; in particular, her potassium
l e v e lw a s3 . 5m m o lL
-1 (3.3-4.9 mmol L
-1). She was
asymptomatic up till this event. In particular, there was
no intervening symptom of vomiting or diarrhoea, and
the patient did not report the use of any oral medica-
tions. The patient did not have prior hypokalemia up to
this point. Electrolytes drawn immediately upon onset of
neurological symptoms revealed acute hypokalemia, with
a serum potassium level of 2.5 mmol L
-1 with a normal
serum bicarbonate level of 23.1 mmol L
-1 (19.0-31.0
mmol L
-1), normal corrected serum total calcium level
of 2.28 (2.10-2.60 mmol L
-1)a n dm a g n e s i u ml e v e lo f
0.78 mmol/L (0.70-0.95 mmol L
-1).
The patient was placed in a warm environment and an
aggressive potassium replacement was undertaken. She
did not receive calcium or magnesium infusions. The
bilateral abducens neuropathy, dysarthria and laryngo-
pharyngodysesthesia resolved over two hours. The hypo-
kalemia, perioral and peripheral numbness resolved over
twelve hours. Due to the short duration of the episode,
no electromyogram (EMG) or nerve conduction testing
was performed. The diffuse T-wave inversions on ECG
did not resolve and remained six months following this
event.
The patient was re-challenged with the same dose of
oxaliplatin for her fourth cycle, with infusion time
extended from 2 to 6 hours, together with calcium and
magnesium infusions, and did not experience subse-
quent neurotoxicity. She continued to receive second-
line irinotecan and cisplatin, third-line docetaxel, fourth-
line epirubicin, cisplatin and 5-fluorouracil and fifth line
5-fluorouracil and cetuximab. All treatments were toler-
ated reasonably without further adverse events. The
patient eventually passed away from progressive disease
approximately fifteen months after initial diagnosis
while on best supportive care.
Discussion
While the mechanism of oxaliplatin neurotoxicity
remains uncertain, EMG studies have demonstrated per-
ipheral motor nerve hyperexcitability coinciding with
symptoms of acute neuropathy, including cold-induced
paresthesias and larygopharyngodysesthesias [6]. It is
conventionally regarded that voltage-gated sodium chan-
nels are involved. Preclinical studies showed that oxali-
platin causes prolonged opening of voltage-gated
sodium channels in sensory nerves with a resulting
hyperexcitable state [7]. It has been suggested in precli-
nical studies that oxaliplatin may mediate this channelo-
pathy through the rapid chelation of unbound calcium
through its oxalate metabolite [4].
A previous ex vivo study investigating voltage-gated
potassium channels using blockers such as apamin has
been performed, with no apparent correlation between
phenotypes induced by apamin and acute oxaliplatin
neurotoxicity [8]. The authors, however, argue that a
population of apamin-resistant, calcium-dependent
potassium channels has been identified, and that cal-
cium chelation by oxalate provides a viable mechanism
for this to occur. Indeed, recently reported ex vivo work
suggests that oxaliplatin may interfere with voltage-
gated potassium channels [9,10]. Unexpectedly, one of
these two reports did not detect an effect of oxaliplatin
on voltage-gated sodium channels [10].
A single case report previously has reported an asso-
ciation between oxaliplatin and bilateral abducens nerve
palsy in a patient heavily exposed to previous cisplatin
[11], but did not report on the phenomenon of post-
tetanic facilitation or associated hypokalemia. Post-teta-
nic facilitation has not been previously recognized, and
may imply the involvement of voltage-gated channels in
the presynaptic terminal, where both potassium and cal-
cium channels are present. Calcium-activated presynap-
tic potassium channels in Xenopus are known to
regulate transmitter release magnitude during single
action potentials by altering the rate of action potential
repolarization, and thus the magnitude of peak calcium
current [12].
The acute hypokalemia we observe has been reported
i nas e p a r a t ec a s er e p o r tw h e r eac o m aa s s o c i a t e dw i t h
hypokalemia and hypocalcemia was reported after infu-
sion of oxaliplatin [13]. The mechanism is uncertain.
Given that our patient presented with hypokalemia but
not hypocalcemia, the data does not support systemic
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oxaliplatin-induced neurotoxicity, but it is conceivable
that a specific locations along the peripheral nerve may
be more vulnerable to accumulation of oxaliplatin or its
metabolites [1]. For example, platinum has been shown
to accumulate in dorsal root ganglia in rodents adminis-
tered oxaliplatin.
We considered the possibility of the acute hypokale-
mia causing the post-tetanic facilitation that we
observed. Acute hypokalemia is associated with axonal
and muscle membrane hyperpolarization [14,15]. It
must be acknowledged that although our review of the
literature did not report a previous association between
hypokalemia and post-tetanic facilitation, the mechan-
isms of hypokalemia in inducing weakness are complex
and as-yet poorly understood. Hence, a possible contri-
bution of hypokalemia to post-tetanic facilitation cannot
be definitively excluded. However, recent electrophysio-
logic investigations of patients with acute hypokalemia
highlight its contribution to axonal hyperpolarization,
with a resulting activity-dependent conduction block
worsening, rather than improving weakness [14]. Hence,
this data suggests that hypokalemia is not the primary
mechanism for post-tetanic facilitation.
Conclusion
In summary, while the mechanism of acute oxaliplatin-
induced neuropathy remains uncertain, our novel clini-
cal observation of post-tetanic facilitation alongside
acute hypokalemia highlights voltage-gated channels at
the presynaptic nerve terminal for investigation in the
mechanism of acute oxaliplatin neurotoxicity.
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Written informed consent was obtained from the
patient’s family for publication of this case report. A
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the Editor-in-Chief of this journal.
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